Reduction in the therapeutic intensity of abortive migraine drug use during ACE inhibition therapy - A pilot study

Pharmacoepidemiology and Drug Safety

Volumn 13, Issue 1, 2004, Pages 41-47

  Rahimtoola, H ^a,b   Buurma, H ^b   Tijssen, C C ^c   Leufkens, H G ^a   Egberts, A C G ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b SIR Institute for Pharmacy Practice and Policy   (Netherlands)

^c CPRLab   (Netherlands)

^d GGZ Midden Brabant   (Netherlands)

Author keywords

ACE inhibitors; Migraine; Triptans

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIMIGRAINE AGENT; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERGOTAMINE; LOOP DIURETIC AGENT; LOSARTAN; NARATRIPTAN; POTASSIUM SPARING DIURETIC AGENT; RIZATRIPTAN; SUMATRIPTAN; THIAZIDE DIURETIC AGENT; ZOLMITRIPTAN;

ADULT; ARTICLE; CONTROLLED STUDY; DATA BASE; DISEASE ACTIVITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; ENZYME INHIBITION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MIGRAINE; PILOT STUDY; PRESCRIPTION; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DRUG UTILIZATION; ERGOTAMINE; FEMALE; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; PILOT PROJECTS; RECEPTOR, ANGIOTENSIN, TYPE 2; RETROSPECTIVE STUDIES; SEROTONIN AGONISTS;

EID: 0742307191     PISSN: 10538569     EISSN: None     Source Type: Journal    
DOI: 10.1002/pds.893     Document Type: Article

References (25)

1. Lipton RB, Stewart WF, von Korff M. Burden of migraine: societal costs and therapeutic opportunities. Neurology 1997; 48(Suppl. 3): S4-S9.
2. Limmroth V, Michel MC. The prevention of migraine: a critical review with special emphasis on β-adrenoceptor blockers. Br J Clin Pharm 2001; 52: 237-243.
3. d' Amato CC, Pizza V, Marmolo T, et al. Fluoxetine for migraine prophylaxis: a double-blind trial. Headache 1999; 39: 716-719.
4. Schoenen J, Jacquy J, Lenaerts M. Effectiveness of high-dose riboflavin in migraine prophylaxis: a randomised controlled trial. Neurology 1998: 50: 466-470.
5. Mauskop A, Altura BM. Role of magnesium in the pathogenesis and treatment of migraines. Clin Neurosci 1998: 5: 24-27.
6. Morales-Asin F, Iniguez C, Cornudella R, et al. Patients with acenocoumarol treatment and migraine. Headache 2000; 40: 45-47.
7. Schrader H, Stovner LJ, Helde G, et al. Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study. Br Med J 2001; 322: 1-5.
8. Luscher TF. Angiotensin, ACE-inhibitors and endothelial control of vasomotor tone. Basic Res Cardiol 1993; 88(Suppl. 1): 15-24.
9. Montgomery L. Are angiotensin-converting enzyme (ACE) inhibitors effective in preventing migraine in nonhypertensive patients? J Fam Pract 2001; 50: 1-2.
10. Etminan M, Tomlinson G, Levine MA, Rochon PA. Efficacy of Angiotensin II receptor antagonists in preventing headache: systematic overview and meta-regression analysis. Pharmacoepidemiol Drug Safe 2001; 10(Suppl. 1): S1.
11. Herings RMC. PHARMO; a record linkage system for post-marketting surveillance of precription drugs in The Netherlands [Dissertation]. Utrecht University 1993.
12. Anonymous. Anatomical Therapeutic Chemical (ATC) classification index. WHO Collaborating Centre for Drug Statistics Methodology: Oslo, 1993.
13. Gaist D, Halls J, Sindrup SH, Gram LF. Is overuse of sumatriptan a problem? A population based study. Eur J Clin Pharmacol 1996; 50: 161-165.
14. Bender WI. ACE inhibitors for prophylaxis of migraine headaches. Headache 1995; 35: 470-471.
15. Fabiani ME, Johnston CI. Spectrum of use for the angiotensin-receptor blocking drugs. Cur Hypertens Rep 1999; 1: 394-401.
16. Martelletti P, Cugini P, Letizia C, et al. Chronopathology for angiotensin converting enzyme circadian rhythm in migraine. Chronobiologia 1990; 17: 59-64.
17. Paterna S, Di Pasquale P, D'Angelo A, et al. Angiotensin-converting enzyme gene deletion polymorphism determines an increase in frequency of migraine attacks in patients suffering from migraine without aura. Eur Neurol 2000; 43: 133-136.
18. Petri H, de Vet HCW, Naus J, Urquhart J. Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 1988; 7: 1171-1175.
19. Rahimtoola H, Egberts ACG, Buurma H, Tijssen CC, Leufkens HG. Reduction in the intensity of abortive migraine drug use during coumarin therapy. Headache 2001; 41: 768-773.
20. Hallas J, Nissen A. Individualised drug utilisation statistics: analysing a population's drug use from the perspective of individual users. Eur J Clin Pharmacol 1994; 47: 367-372.
21. Rasmussen BK, Jensen R, Schroll M, Olesen J. Epidemiology of headache in a general population - a prevalence study. J Clin Epidemiol 1991; 44: 1147-1157.
22. D'Allessandro R, Gamberini G, Benassi G, Morganti G, Cortelli P, Lugaressi E. Cluster headache in the Republic of San Marino. Cephalagia 1986; 6: 159-162.
23. Mathew NT. Migraine and hypertension. Cephalalgia 1999; 19(Suppl. 25): S17-S19.
24. Van den Brink A, Reekers M, Bax WA, Ferrari MD, Saxena PR. Coronary side-effect potential of current and prospective antimigraine drugs. Circulation 1998; 98: 25-30.
25. Young WB, Mannix L, Adelman U, Aaron L, Schecter A. Cardiac risk factors and the use of triptans: a survey study. Headache 2000; 40: 587-591.